Inclusive of all taxes
Lucrin Depot 3.75 mg / 11.25 mg Injection is a potent long-acting injectable formulation of Leuprolide Acetate, designed for targeted hormonal therapy in various hormone-dependent conditions. Manufactured by Abbott / AbbVie, Lucrin Depot acts as a Gonadotropin-Releasing Hormone (GnRH) agonist, effectively suppressing the pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression leads to a significant decrease in sex hormone production, including testosterone in men and estrogen in women, thereby controlling disease progression in conditions such as advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty (CPP) in pediatric patients. Available in two dosage strengths, 3.75 mg for monthly administration and 11.25 mg for quarterly administration, Lucrin Depot offers flexibility and ease of use in clinical settings. The formulation requires reconstitution from a vial with sterile diluent and is administered intramuscularly or subcutaneously by healthcare professionals, ensuring precise dosing and safety. The long-acting depot ensures steady hormonal suppression, improving symptom management and delaying disease progression. Strict storage conditions and medical supervision are necessary to maintain efficacy and patient safety.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Leuprolide Acetate |
| Formulation Type | Long-acting injectable depot |
| Available Strengths | 3.75 mg (1-month), 11.25 mg (3-month) |
| Therapeutic Use | Hormonal therapy for prostate cancer, endometriosis, uterine fibroids, CPP |
| Route of Administration | Intramuscular or subcutaneous injection |
| Dosage Frequency | Monthly for 3.75 mg; every 3 months for 11.25 mg |
| Packaging | Vial with sterile diluent for reconstitution, single-use pack |
| Storage Conditions | 2°C – 8°C, protect from light, do not freeze |
| Manufacturer | Abbott / AbbVie |
| Approval Status | Prescription-only medication under strict medical supervision |
| Attributes | Description |
|---|---|
| Generic Name | Leuprolide Acetate |
| Therapeutic Category | Hormonal Therapy / GnRH Agonist |
| Indications | Advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty |
| Dosage Form | Injection (Depot) |
| Injection Type | Intramuscular (IM) or subcutaneous (SC) |
| Dosage Strengths | 3.75 mg and 11.25 mg per vial |
| Frequency of Administration | Monthly or every 3 months |
| Storage Requirements | Refrigerate at 2°C – 8°C, away from light, avoid freezing |
| Packaging Details | Single-use vial with sterile diluent for reconstitution |
| Contraindications | Pregnancy, breastfeeding |
| Precautions | Must be administered by healthcare professionals; monitor hormone levels and bone health |
| Adverse Effects Warning | Initial hormone surge (tumor flare) in prostate cancer patients possible |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The Lucrin Depot 3.75 mg injection is designed for monthly administration, whereas the 11.25 mg injection is formulated for administration every three months, providing greater dosing convenience depending on patient needs.
Lucrin Depot works as a GnRH agonist by continuously stimulating the pituitary gland, which paradoxically suppresses the release of LH and FSH hormones, leading to reduced production of testosterone and estrogen. This hormonal suppression helps in controlling the progression of diseases like prostate cancer and endometriosis.
During the initial treatment phase, Lucrin Depot may cause a temporary surge in testosterone levels (tumor flare), which can worsen symptoms. Close medical supervision and possibly adjunct therapies are essential to manage this effect safely.
Yes, Lucrin Depot injections are intended to be administered by qualified healthcare professionals via intramuscular or subcutaneous injection, making them suitable for use in outpatient clinics or hospital settings.
Lucrin Depot injections must be refrigerated at temperatures between 2°C and 8°C, protected from light, and should never be frozen to ensure stability and potency.
Country Of Origin: India
Product Name: Lucrin Depot 3.75 mg / 11.25 mg Injection
Manufacturer: Abbott / AbbVie
Generic Name:
Leuprolide Acetate
Therapeutic Category:
Hormonal Therapy / Gonadotropin-Releasing Hormone (GnRH) Agonist
Product Description:
Lucrin Depot is a long-acting injectable formulation of Leuprolide Acetate, a synthetic analogue of gonadotropin-releasing hormone (GnRH). It is widely used in the treatment of hormone-dependent conditions, particularly prostate cancer, endometriosis, and uterine fibroids.
By continuously stimulating the pituitary gland, Leuprolide suppresses the release of gonadotropins (LH and FSH), leading to decreased production of sex hormones (testosterone in men, estrogen in women).
Available Strengths:
• Lucrin Depot 3.75 mg Vial – 1-month depot injection
• Lucrin Depot 11.25 mg Vial – 3-month depot injection
Indications:
• Advanced prostate cancer (androgen-dependent)
• Endometriosis (symptom management)
• Uterine fibroids (preoperative management)
• Central Precocious Puberty (CPP) in children
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
